Skip to main content

Advertisement

Log in

Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR

  • Invited Feature Section
  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Nowadays, the diagnosis of hepatocellular carcinoma (HCC) is increasingly demanded to imaging techniques. Anyway, imaging cirrhotic patients still remains a challenging issue, since pre-neoplastic hepatocellular lesions, as dysplastic nodules (DNs), may frequently mimic small neoplasms. Differently from other imaging modalities, magnetic resonance (MR) can give an accurate evaluation of both intracellular and vascular changes occurring during the carcinogenetic pathway from dysplasia to full malignancy. Both DNs and HCC may in fact show a large variety of signal intensities, strictly reflecting nodules’ characteristics, such as lesion architecture, grading, stromal components, as well as intracellular contents. In these last years, the introduction of dedicated contrast media has increased MR diagnostic efficacy, permitting to explore both vascular as well as the pathological changes occurring in the biliary and reticuloendothelial systems during the carcinogenetic process. MR performed with tissue specific contrast agents (hepatobiliary and reticulo-endothelial) may thus give an insight on this “gray area”, in whom significant histological changes are already present without an evident nodule arterial supply. This peculiar MR prerogative permits to give predictive information about the evolution trend in a cirrhotic parenchyma and to identify patients at high risk for developing carcinoma who would benefit from well-timed treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530

    Article  PubMed  Google Scholar 

  2. MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone

    Google Scholar 

  3. Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466

    Article  Google Scholar 

  4. Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71

    Article  PubMed  Google Scholar 

  5. Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681

    Article  PubMed  Google Scholar 

  6. Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578

    Article  PubMed  Google Scholar 

  7. Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809

    Article  PubMed  CAS  Google Scholar 

  8. Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72

    CAS  Google Scholar 

  9. Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89

    Article  PubMed  Google Scholar 

  10. Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

    PubMed  CAS  Google Scholar 

  11. Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172

    Article  PubMed  Google Scholar 

  12. Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141

    Article  Google Scholar 

  13. Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748

    Article  PubMed  Google Scholar 

  14. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276

    PubMed  Google Scholar 

  15. Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199

    Article  PubMed  Google Scholar 

  16. Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134

    Article  PubMed  Google Scholar 

  17. Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394

    PubMed  CAS  Google Scholar 

  18. Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69

    PubMed  Google Scholar 

  19. Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566

    Article  PubMed  Google Scholar 

  20. Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488

    PubMed  CAS  Google Scholar 

  21. Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178

    Article  PubMed  CAS  Google Scholar 

  22. International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664

    Article  Google Scholar 

  23. Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512

    Article  PubMed  Google Scholar 

  24. Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519

    Article  Google Scholar 

  25. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430

    Article  PubMed  CAS  Google Scholar 

  26. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236

    Article  PubMed  Google Scholar 

  27. Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210

    Article  PubMed  CAS  Google Scholar 

  28. Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676

    Article  PubMed  CAS  Google Scholar 

  29. Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805

    Article  PubMed  CAS  Google Scholar 

  30. Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693

    Article  Google Scholar 

  31. Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlo Bartolozzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartolozzi, C., Battaglia, V. & Bozzi, E. Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36, 290–299 (2011). https://doi.org/10.1007/s00261-011-9687-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-011-9687-z

Keywords

Navigation